The best way to play the biotech boom

Syncona is an unusual investment trust that invests in promising privately held biotech companies. It should be a core holding in any portfolio, says David Stevenson.

Scientist working in a laboratory © iStockphotos

Syncona: buy while the entry price is right

Syncona is an unusual investment trust that invests in promising privately held biotech companies. It should be a core holding in any portfolio, says David Stevenson.

Investors in the biotech sector have had a tough time over the last year. High valuations and concern over regulators and politicians attempting to lower drug prices have hit the Nasdaq Biotech index, which contains 220 companies. This benchmark has fallen by 11.39% over the last 12 months, compared with a gain of 18.7% for the S&P 500 index.

The long-term growth story, however, remains compelling. An ageing society is demanding better, more targeted medicines and technology is rising to the occasion, as the genomics-led revolution in care shows. Big Pharma gets the story, which is why it's been buying into the sector for the last few years in order to replenish its portfolios.

The best way in

But listed businesses only represent a portion of the available biotech universe of businesses. Many of the most interesting firms are privately held, usually with venture-capital firms as investors. Few vehicles provide access to this sector.

In my view the core holding for biotech investors should be Syncona (LSE: SYNC). I've held shares in this fund for years and I recently topped up my holdings. I think it is by far the best way of accessing privately held biotech firms. Recent share-price weakness offers an excellent chance to get on board.

The Syncona story is unusual. It started out as an independent investment business trading within the Wellcome Trust. It then merged with a UK trust called BACIT (Battle against Cancer investment trust), which was running a multi-fund portfolio. The merged entity is in effect a world-leading life-sciences venture capitalist joined at the hip with a traditional multi-fund manager kicking off cash that can be reinvested in private businesses. Followers of the Warren Buffett approach to investing will spot a classic ploy use a cash float from a boring business to provide growth capital for equity investments.

A good eye for winners

Syncona passes this challenge easily. It's already produced two exits in its short listed life. Blue Earth Diagnostics, the prostate-cancer imaging company, was sold to Bracco Imaging in late June. The other was Nightstar Therapeutics, a Nasdaq-listed retinal gene-therapy company. Syncona made a tenfold and a 4.5-fold return on these two companies respectively. Since December 2016 Syncona's share price has risen by around 70%, while its net asset value (NAV) gained 38% in the year to April. After its recent deals, Syncona is flush with cash worth around £915m, or 70% of assets.

According to funds analysts at Numis, a stockbroker, this might act as a "drag on NAV growth in the near term, but leaves the business well-financed to support growth in its existing portfolio, as well as to support new initiatives".

We can certainly see that last point emerging at the portfolio level. Syncona has founded three new portfolio companies over the past year: OMass Therapeutics (drug discovery), Anaveon (immuno-oncology), and Quell Therapeutics (cell therapy).

A treatment for haemophilia

But not every business in its portfolio has had such good luck. One portfolio business called Autolus Therapeutics, which is a Nasdaq-listed company, has seen its share price fall 47% since April, driven lower in part by worries that co-investor Neil Woodford might sell stock to help with his own issues. It's not too difficult to see why investors might be wary. The portfolio has a young, risky feel to it. There's a mountain of cash that will need to be invested to make a return, probably at the rate of between £100m and £200m per annum. And investors have slightly soured on biotech firms more generally. As a result, Syncona's share price is down by 6.7% over the last six months. At approximately 245p a share, it is trading at roughly 20% above the NAV based on calculations from Numis. For a potential high-growth fund, that looks to me like a more than decent entry price.

Recommended

Larry Fink: the undisputed king of Wall Street
People

Larry Fink: the undisputed king of Wall Street

Larry Fink survived two big financial crises and went on to build a massive asset manager, doing for investing what Henry Ford did for cars. He has hi…
23 Oct 2021
Back on track: why you should invest in railways
Share tips

Back on track: why you should invest in railways

Rail transport suffered a severe blow in the pandemic. But while post-Covid-19 working patterns may reduce revenue, trends in technology, long-distanc…
22 Oct 2021
Airtel Africa has growth on speed dial. Here's how to play it
Trading

Airtel Africa has growth on speed dial. Here's how to play it

Mobile-phone group Airtel Africa is cashing in on the rise of the continent's digital economy and looks set for years of rapid expansion, says Matthew…
22 Oct 2021
Share tips of the week – 22 October
Share tips

Share tips of the week – 22 October

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
22 Oct 2021

Most Popular

How to invest as we move to a hydrogen economy
Energy

How to invest as we move to a hydrogen economy

The government has started to roll out its plans for switching us over from fossil fuels to hydrogen and renewable energy. Should investors buy in? St…
8 Oct 2021
Properties for sale for around £1m
Houses for sale

Properties for sale for around £1m

From a stone-built farmhouse in the Snowdonia National Park, to a Victorian terraced house close to London’s Regent’s Canal, eight of the best propert…
15 Oct 2021
How to invest in SMRs – the future of green energy
Energy

How to invest in SMRs – the future of green energy

The UK’s electricity supply needs to be more robust for days when the wind doesn’t blow. We need nuclear power, says Dominic Frisby. And the future of…
6 Oct 2021